Bridgewater, NJ, August 7, 2017 Neurotez, Inc. today announced that Bob Oliver, most recently President and CEO of Otsuka America Pharmaceutical, Inc. is joining the Board of Directors of Neurotez. “Mr. Oliver is a prominent and effective leadership figure in the pharmaceutical industry with deep knowledge and success in drug development and commercialization efforts in the CNS landscape among others and particularly familiar with the challenges for a breakthrough medicine in Alzheimer’s disease.
We are honored and delighted Bob is sharing our vision for our company and for his support of our flagship asset, Memtin for prodromal AD”, said Nikolaos Tezapsidis, President & CEO of Neurotez. “Bob brings the experience and talents essential to propel Neurotez to the next level” said George Perry CSO of Neurotez. “I am excited to get to work with the Neurotez Directors and Management Team to advance Memtin as we seek to validate our Leptin hypothesis for the good of Alzheimer’s patients said Mr. Oliver”.
About Bob Oliver.
Bob Oliver most recently served as President and CEO of Otsuka America Pharmaceutical, Inc., (OAPI). He was responsible for overseeing OAPI’s diverse and growing product . portfolio across the neuroscience, cardiovascular, oncology, and medical device markets. Bob drove the organization toward a vision that reached beyond innovative medicines to provide solutions, access, and education, encouraging employees to view their work as fighting disease, confronting stigma, and resisting the status quo. Prior to joining Otsuka, Bob was Vice President and Global Business Manager for Oncology at Wyeth. Bob also gave leadership to the Vaccines Division and Primary Care at Wyeth while eventually assuming responsibility for U.S. Commercial Operations including Puerto Rico and the Caribbean.
Bob began his career in pharmaceuticals with Johnson & Johnson, holding positions of increasing responsibility in sales, marketing, business operations and corporate management. Bob earned a bachelor’s degree from Rutgers University and an M.B.A. degree in Marketing from the Haub School of Business at Saint Joseph’s University, where he now sits on the Pharma Board of Advisors. Bob also serves as a member of the Board for Academic Fellows at Eastern University, where he mentors doctoral candidates. Bob also serves as Board Chairman for Otsuka Canada Pharmaceuticals, Inc.; and is an Executive Advisor and Board member of Hyalo Technologies, a Biotech start up.
About Neurotez, Inc.
Neurotez Inc., a CNS biotechnology company founded in 2005, is a privately held Delaware corporation operating from New Jersey. Neurotez used biochemical, molecular & cell biology and in vivo models to screen, identify and characterize suitable candidate biopharmaceuticals targeting major Central Nervous System (CNS) disorders with unmet medical need. It aims to evolve to a company with a fully-integrated platform that spans activities from discovery to proof of concept clinical trials. Neurotez’s flagship asset is Memtin, a Leptin product, currently under preparation for clinical development as a hormone replacement therapy for Alzheimer’s disease, and as a preventative remedy to those at risk.
To find out more, please visit www.neurotez.com.
Contacts Jane Johnston, PhD, Executive Director
+1-908-998-1340
jmjohnston@neurotez.com
Neurotez, Inc.,
991 Highway 22, Suite 200A,
Bridgewater, NJ 08807
